GMAB Stock Forecast & Price Target

Genmab is poised for success in the oncology market with its strong pipeline of novel antibody therapeutics and partnerships with major pharmaceutical companies like Johnson & Johnson, AbbVie, and Novartis. The company's leading product, Darzalex, is already a standard of care for multiple myeloma and has potential for further growth. Additionally, its other pipeline candidates targeting various cancers, such as Tepezza for thyroid eye disease and Kesimpta for relapsing multiple sclerosis, provide opportunities for diversification and future revenue potential. With strong financials, a 2026 financial guidance raise, and a promising upcoming Phase 3 data readout for Epkinly, Genmab is well-positioned for continued success in the market and potential for significant growth.

Genmab is likely to see increased success and profitability with their EPCORE DLBCL-4 trial results, leading to a higher probability of FDA approval for both 1L and 2L+ settings for EPKINLY. This, combined with their strong partnerships and pipeline candidates, could potentially drive up the stock's value in the long term. However, Genmab's dependence on partnerships for their leading product and their focus solely on oncology may limit their growth potential and make them susceptible to market changes.